Literature DB >> 17640950

Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization.

Fatou Nsoure Obame1, Roland Zini, Rachid Souktani, Alain Berdeaux, Didier Morin.   

Abstract

Opening of the permeability transition pore (PTP) is a key event in ischemia-reperfusion injury and several ligands of the peripheral benzodiazepine receptor (PBR), a mitochondrial outer membrane protein possibly associated with PTP, have been demonstrated as potent cardioprotective agents. Here, we investigated the mechanisms by which the specific PBR ligand 4'-chlorodiazepam (CDZ) protected the myocardium against ischemia-reperfusion. In either global or regional models of myocardial ischemia-reperfusion in rats, CDZ reduced infarct size in a dose-dependent manner (e.g., 11 +/- 1% of the area at risk at 10 mg/kg versus 31 +/- 3% in control; p < 0.05) and to a similar extent as ischemic or diazoxide-induced preconditioning. CDZ (10 mg/kg) reduced apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining), restored mitochondrial recovery, improved oxidative phosphorylation parameters, and reduced mitochondrial membrane permeabilization with inhibition of cytochrome c and apoptosis-inducing factor releases. CDZ increased the resistance of mitochondria to Ca2+-induced PTP opening. All these cardioprotective effects of CDZ were associated with an improved stabilization of the association of Bcl-2 with the mitochondrial membrane and inhibition of the association of a cytosolic fragment of Bax, occurring during ischemia-reperfusion, with the outer mitochondrial membrane. In addition, the PTP opener atractyloside (20 microM) and the Bcl-2 inhibitor ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1) (20 microM) abrogated CDZ-induced reduction of infarct size. These results demonstrate that PBR occupancy by CDZ renders the heart more resistant to ischemia-reperfusion injury by limiting mitochondrial membrane permeabilization. This is due to a reorganization of the balance between pro- and antiapoptotic proteins of the Bcl-2 family proteins at the level of mitochondrial membranes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640950     DOI: 10.1124/jpet.107.124255

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Measuring mitochondrial function in intact cardiac myocytes.

Authors:  Elena N Dedkova; Lothar A Blatter
Journal:  J Mol Cell Cardiol       Date:  2011-09-22       Impact factor: 5.000

2.  Blockade of electron transport during ischemia preserves bcl-2 and inhibits opening of the mitochondrial permeability transition pore.

Authors:  Qun Chen; Edward J Lesnefsky
Journal:  FEBS Lett       Date:  2011-02-25       Impact factor: 4.124

Review 3.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 4.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 5.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

Review 6.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 7.  Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.

Authors:  Vassilios Papadopoulos; Laurent Lecanu
Journal:  Exp Neurol       Date:  2009-05-04       Impact factor: 5.330

Review 8.  Recent progress in the use of mitochondrial membrane permeability transition pore in mitochondrial dysfunction-related disease therapies.

Authors:  Yuting Cui; Mingyue Pan; Jing Ma; Xinhua Song; Weiling Cao; Peng Zhang
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

9.  Translocator protein (Tspo) gene promoter-driven green fluorescent protein synthesis in transgenic mice: an in vivo model to study Tspo transcription.

Authors:  Hui-Jie Wang; Jinjiang Fan; Vassilios Papadopoulos
Journal:  Cell Tissue Res       Date:  2012-08-07       Impact factor: 5.249

Review 10.  Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?

Authors:  P Kleinbongard; G Heusch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.